Advertisement
UK markets close in 3 hours 41 minutes

  • FTSE 100

    8,091.77
    +51.39 (+0.64%)
     

  • FTSE 250

    19,707.77
    -11.60 (-0.06%)
     

  • AIM

    755.16
    +0.47 (+0.06%)
     

  • GBP/EUR

    1.1668
    +0.0023 (+0.20%)
     

  • GBP/USD

    1.2510
    +0.0047 (+0.38%)
     

  • Bitcoin GBP

    51,118.60
    -2,092.62 (-3.93%)
     

  • CMC Crypto 200

    1,356.53
    -26.05 (-1.88%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.91
    +0.10 (+0.12%)
     

  • GOLD FUTURES

    2,341.50
    +3.10 (+0.13%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,960.07
    -128.63 (-0.71%)
     

  • CAC 40

    8,012.30
    -79.56 (-0.98%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Here's Why Innate Pharma Stock Is Rocketing Higher Today

Cory Renauer, The Motley Fool
·2-min read
Here's Why Innate Pharma Stock Is Rocketing Higher Today

Shares of Innate Pharma (NASDAQ: IPHA), a clinical-stage biotechnology company, are rocketing higher in response to successful clinical-trial data for an experimental cancer drug called monalizumab. Monalizumab is currently in a phase 2 trial called Coast, in combination with Imfinzi from AstraZeneca (NASDAQ: AZN). Imfinzi is approved to treat advanced-stage non-small cell lung cancer (NSCLC) patients with tumors that haven't grown since beginning standard first-line treatment.

Continue reading